ABD - İngilizce - NLM (National Library of Medicine)

teva parenteral medicines, inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin 500 mg in 2 ml

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - amikacin, quantity: 500 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; water for injections; sodium metabisulfite - dbl amikacin injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,dbl amikacin injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intraabdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

ABD - İngilizce - NLM (National Library of Medicine)

teva parenteral medicines, inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including postvascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection, are not indicated in uncomplicated initial episodes of urinary tract infec

İsrail - İngilizce - Ministry of Health

a.l. medi-market ltd. - amikacin as sulfate - solution for injection / infusion - amikacin as sulfate 250 mg / 1 ml - amikacin - amikacin - medo is indicated in the short-term treatment of gram-negative organisms, including pseudomonas and some gram-positive organisms.sensitive gram-negative organisms include; pseudomonas aeruginosa, escherichia coli., indole-positive and indole-negative proteus spp., klebsiella, enterobacter and serratia spp., minea-herralae, citrobacter freundii, salmonella, shigella, acinetobacter and providencia spp.the principal gram-positive organism sensitive to amikacin is staphylococcus aureus, including some methicillin-resistant strains. amikacin - medo has some activity against other gram-positive organisms including certain strains of streptococcus pyogenes, enterococci and diplococcus pneumoniae.

ABD - İngilizce - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin sulfate injection usp is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia  coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species, and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection usp to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection usp are not indicated in uncomplicated initial episodes of urin

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - amikacin -

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

caragen limited - amikacin - solution for injection/infusion - 250 milligram(s)/millilitre - amikacin

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - amikacin - solution for infusion - 5 milligram(s)/millilitre - other aminoglycosides; amikacin

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - amikacin sulfate, quantity: 333.76 mg/ml (equivalent: amikacin, qty 250 mg/ml) - injection, solution - excipient ingredients: sodium citrate; water for injections; sulfuric acid; sodium metabisulfite - amiwok is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see microbiology).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics.,amiwok is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post- operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Kanada - İngilizce - Health Canada

searchlight pharma inc - amikacin (amikacin sulfate) - solution - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides